文献速递妇科

吉西他滨联合帕唑帕尼对比吉西他滨单药治疗复发性上皮性卵巢癌的随机II期研究

A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
PubMed 文献 · Gynecol Oncol · 2020-04-01

该开放标签随机多中心II期试验纳入148例铂耐药或铂敏感复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌患者,随机接受每周吉西他滨联合帕唑帕尼或吉西他滨单药治疗。联合组中位无进展生存期显著延长(5.3 vs 2.9个月),铂耐药亚组获益最明显(5.32 vs 2.33个月),总生存无差异,联合组客观缓解率和疾病控制率更高,但≥3级高血压、中性粒细胞减少和血小板减少发生率增加。

要点

  • 吉西他滨联合帕唑帕尼较单药显著延长复发性上皮性卵巢癌的中位无进展生存期(5.3 vs 2.9个月)。
  • 铂耐药亚组从联合治疗中获益最显著(5.32 vs 2.33个月,Tarone-Ware p<0.001)。
  • 联合组客观缓解率和疾病控制率更高,但≥3级高血压、中性粒细胞减少和血小板减少发生率增加。

核心结论

  • 在吉西他滨基础上加用帕唑帕尼可增强抗肿瘤活性,铂耐药患者获益最大,即使既往接受过贝伐珠单抗治疗。

研究设计与样本

  • 开放标签、随机、多中心II期试验(NCT01610206),纳入148例铂耐药或铂敏感、≤3线既往化疗、可测量/可评估的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌患者。
  • 患者随机接受每周吉西他滨1000 mg/m2(第1、8天,21天周期)联合帕唑帕尼800 mg每日一次或吉西他滨单药,按铂敏感性和既往治疗线数(1 vs 2或3)分层。
  • 主要终点为无进展生存期(PFS)。

主要发现

  • 中位年龄63岁(范围30-82),60%为铂耐药,中位随访13个月(范围0.4-54个月)。
  • 联合组中位PFS为5.3个月(95%CI 4.2-5.8),单药组为2.9个月(95%CI 2.1-4.1)。
  • 铂耐药组中位PFS为5.32 vs 2.33个月(Tarone-Ware p<0.001)。
  • 总生存无差异;联合组总体缓解率(PR 20% vs 11%,卡方p=0.02)和疾病控制率(80% vs 60%,卡方p<0.001)更高。
  • 联合组≥3级不良事件包括高血压(15%)、中性粒细胞减少(35%)和血小板减少(12%)。

关键数值与推荐

  • 联合组中位PFS 5.3个月(95%CI 4.2-5.8) vs 单药组2.9个月(95%CI 2.1-4.1)。
  • 铂耐药组中位PFS 5.32 vs 2.33个月(Tarone-Ware p<0.001)。
  • 总体缓解率(PR)20% vs 11%(卡方p=0.02);疾病控制率80% vs 60%(卡方p<0.001)。
  • 联合组≥3级高血压15%、中性粒细胞减少35%、血小板减少12%。

临床怎么用

  • 对于铂耐药复发性上皮性卵巢癌患者,可考虑吉西他滨联合帕唑帕尼以延长无进展生存期。
  • 联合治疗时需监测高血压、中性粒细胞减少和血小板减少等≥3级不良事件。

局限性

  • 本研究为II期试验,样本量有限(148例),结果需III期试验验证。
  • 总生存未见差异,联合治疗对总生存的影响尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Angiogenesis inhibition is a valuable strategy for ovarian cancer (EOC). Pazopanib (paz) is a potent small molecular inhibitor of VEGF-1, -2, -3, PDGFR, c-kit, and has activity as a single agent in ovarian cancer. We designed a trial to assess the benefit of adding paz to gemcitabine (gem) in patients with recurrent EOC. METHODS: An open-label, randomized, multi-site, phase 2 trial was conducted (NCT01610206) including patients with platinum resistant or sensitive disease, ≤ 3 prior lines of chemotherapy, and measurable/evaluable disease. Patients were randomly assigned to weekly gem 1000 mg/m2 on days 1 and 8 of a 21 day cycle, with or without paz 800 mg QD, stratified by platinum sensitivity and number of prior lines (1 vs 2 or 3). The primary endpoint was PFS. RESULTS: 148 patients were enrolled 2012-2017. Median age was 63 years (30-82); 60% were platinum resistant; median surveillance was 13 months (0.4-54 months). Median PFS was 5.3 (95% CI, 4.2-5.8) vs 2.9 months (95% CI, 2.1-4.1) in the gem arm. The PFS effect was most pronounced in the platinum resistant group (5.32 vs 2.33 months Tarone-Ware p < 0.001). There was no difference in OS. Overall RR (PR 20% vs 11%, Chi-squre p = 0.02) and DCR (80% vs 60%, Chi-square p < 0.001) were higher in the combination. High grade AEs in the combination arm included ≥ Grade 3: hypertension (15%), neutropenia (35%), and thrombocytopenia (12%). CONCLUSIONS: The addition of paz to gem enhanced anti-tumor activity; those with platinum-resistant disease derived the most benefit from combination therapy, even in the setting of receiving prior bevacizumab.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Duska LR, Petroni GR, Varhegyi N, et al. A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol. 2020. PMID: 32247603. doi:10.1016/j.ygyno.2019.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。